검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | GD2 CAR T cells |
Overview Company | Alex's Lemonade Stand Foundation |
Overview Modality | CGT |
Overview Target | GD2 |
Overview Indication | Neuroblastoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | CAR-T therapy in ALK-mutant NB primarily by attenuating PD-L1-mediated immune evasion, supporting its potential as a combinatorial therapeutic strateg |
MoA Biomarker | PD-L1) expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | GD2T IF cells as a platform for single-dose and long-term delivery of biologics.. The efficacy of biologics, such as peptide and protein drugs, is often limited by their short half-lives in vivo, necessitating repeated infusions to maintain therapeutic effects. Here, we demonstrate that long-lived CAR T cells can be leveraged as a versatile platform for long-term delivery of biologics. Our recent … |
Toxicology CRS | Reported |
Clinical PFS | 122 |
Clinical OS | 170 |
Clinical Result source | ClinicalTrials.gov NCT02761915 |
Clinical Data Tier / Score | A · 36 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | GD2 CAR T cells |
Overview Company | Alex's Lemonade Stand Foundation |
Overview Modality | CGT |
Overview Target | GD2 |
Overview Indication | Neuroblastoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | CAR-T therapy in ALK-mutant NB primarily by attenuating PD-L1-mediated immune evasion, supporting its potential as a combinatorial therapeutic strateg |
MoA Biomarker | PD-L1) expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | GD2T IF cells as a platform for single-dose and long-term delivery of biologics.. The efficacy of biologics, such as peptide and protein drugs, is often limited by their short half-lives in vivo, necessitating repeated infusions to maintain therapeutic effects. Here, we demonstrate that long-lived CAR T cells can be leveraged as a versatile platform for long-term delivery of biologics. Our recent … |
Toxicology CRS | Reported |
Clinical PFS | 122 |
Clinical OS | 170 |
Clinical Result source | ClinicalTrials.gov NCT02761915 |
Clinical Data Tier / Score | A · 36 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교